EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Cerebral Amyloid Angiopathy in Patients with Cognitive Impairment: Cerebrospinal Fluid Biomarkers

Kasia Gustaw Rothenberg, Lynn Bekris, James B Leverenz, Jenny Wu, Jonathan Lee, Volodymyr Statsevych, Paul Ruggieri, Stephen E Jones

Dementia and Geriatric Cognitive Disorders · 2024

DOI: 10.1159/000539884 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Dementia and Geriatric Cognitive Disorders, 2024. Verfasst von Kasia Gustaw Rothenberg und 7 weiteren Autor:innen. Beteiligte Einrichtung: Lou Ruvo Center for Brain Health, Neurological Institute, Cleveland Clinic, Cleveland, Ohio, USA. Hauptthemen laut MEDLINE: Cerebral Amyloid Angiopathy, Amyloid beta-Peptides, Cognitive Dysfunction, Biomarkers. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NIA NIH HHS, NINDS NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Cerebral amyloid angiopathy (CAA) is characterized by amyloid β (Aβ) deposition in brain vessels, leading to hemorrhagic phenomena and cognitive impairment. Magnetic resonance imaging (MRI)-based criteria allow a diagnosis of probable CAA in vivo, but such a diagnosis cannot predict the eventual development of CAA.

Methods

We conducted a retrospective cohort study of 464 patients with cognitive disorders whose data were included in a brain health biobank. De-identified parameters including sex, age, cognitive score, APOE status, and cerebrospinal fluid (CSF) levels of Aβ 1–40, Aβ 1–42, phosphorylated tau, and total tau were assessed in those with and without CAA. Odds ratios (ORs) and 95% confidence intervals (CIs) were determined.

Results

CAA was present in 53 of 464 (11.5%) patients. P-tau level was significantly higher in those with CAA (115 vs. 84.3 pg/mL p = 0.038). In univariate analyses, the risk of developing CAA was higher with increased age (OR, 1.036; 95% CI: 1.008, 1.064; p = 0.011) and decreased CSF level of Aβ 1–40 (OR, 0.685; 95% CI: 0.534, 0.878; p = 0.003). In multivariate analyses, the risk of CAA remained higher with a decreased CSF level of Aβ 1–40 (OR, 0.681; 95% CI: 0.531, 0.874; p = 0.003).

Conclusion

These findings suggest that Aβ 1–40 levels in the CSF might be a useful molecular biomarker of CAA in patients with dementia.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cerebral Amyloid AngiopathyAmyloid beta-PeptidesCognitive DysfunctionBiomarkerstau ProteinsHumansMaleFemaleAgedRetrospective StudiesMiddle AgedPeptide FragmentsAged, 80 and overMagnetic Resonance Imaging

Stichwörter der Autor:innen

APOECerebral amyloid angiopathyDementiaMagnetic resonance imaging

Substanzen

Amyloid beta-PeptidesBiomarkerstau ProteinsPeptide Fragmentsamyloid beta-protein (1-42)

Autor:innen und Institutionen

  • Lou Ruvo Center for Brain Health, Neurological Institute, Cleveland Clinic, Cleveland, Ohio, USA.
  • Genomic Medicine Institute Lerner Research Institute, Cleveland Clinic, Cleveland, Ohio, USA.
  • Department of Radiology, Cleveland Clinic, Cleveland, Ohio, USA.

Förderung

  • NIA NIH HHS
  • NINDS NIH HHS

Zitieren

APA

Rothenberg, K. G., Bekris, L., Leverenz, J. B., Wu, J., Lee, J., Statsevych, V., Ruggieri, P., & Jones, S. E. (2024). Cerebral Amyloid Angiopathy in Patients with Cognitive Impairment: Cerebrospinal Fluid Biomarkers. Dementia and Geriatric Cognitive Disorders. https://doi.org/10.1159/000539884

Vancouver

Rothenberg KG, Bekris L, Leverenz JB, Wu J, Lee J, Statsevych V, et al. Cerebral Amyloid Angiopathy in Patients with Cognitive Impairment: Cerebrospinal Fluid Biomarkers. Dementia and Geriatric Cognitive Disorders. 2024. doi:10.1159/000539884

BibTeX
@article{Rothenberg2024,
  author = {Rothenberg, Kasia Gustaw and Bekris, Lynn and Leverenz, James B and Wu, Jenny and Lee, Jonathan and Statsevych, Volodymyr and Ruggieri, Paul and Jones, Stephen E},
  title = {Cerebral Amyloid Angiopathy in Patients with Cognitive Impairment: Cerebrospinal Fluid Biomarkers},
  journal = {Dementia and Geriatric Cognitive Disorders},
  year = {2024},
  doi = {10.1159/000539884}
}
Kostenlos starten →